Skip to main content
. 2024 Oct 4;10(40):eadn8760. doi: 10.1126/sciadv.adn8760

Fig. 7. TRAIL-R2 activation stimulates angiogenesis.

Fig. 7.

(A) Laser Doppler imaging showing blood perfusion in HLI TrailEC−/− mice treated with MD5-1 or IgG over 7 days (1 μg I.M., 2 days before, 2 days after, and 6 days after surgery). Left: Representative image at 7 days. Right: Quantification over time and (B) stable microvessel numbers (CD31+SMA+) in gastrocnemius from ischemic limbs (n = 6 to 7 per group). (C) mRNA expression of Hbegf and its receptors Erbb2 and Egfr, and Lamc1 and its receptors Itgα1 and Itgb1 in gastrocnemius muscle of mice, normalized to β-actin (n = 5 to 6 per genotype). (D) Laser Doppler imaging showing blood perfusion in HLI Trail-R+/+ and Trail-R−/− mice over 28 days. Left: Representative image at 28 days. Right: Quantification over time and (E) stable microvessel numbers (CD31+SMA+) in gastrocnemius from ischemic limbs 28 days after HLI (n = 5 to 6 per group). (F) Sprouting in blood vessels harvested from ischemic tissues of patients with PAD undergoing below-knee amputation. Vessels were exposed to Conatumumab or IgG (500 ng/ml) for 7 days; scale bars, 200 μm. (G) Quantification of sprout area (white dotted lines), normalized to vessel segment area using ImageJ (n = 3 per treatment). Results are means ± SEM; Students t test; *P < 0.05 and **P < 0.01.